NCT05926349View on ClinicalTrials.gov

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 2, 2024

Primary Completion Date

January 5, 2027

Study Completion Date

September 7, 2027

Conditions
Urgent Surgery
Interventions
DRUG

Andexanet alfa

Andexanet is a recombinant version of human FXa

DRUG

Usual Care

As per the label of the chosen usual care product(s) and/or usual care standards.

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY